Omvoh four-year UC clearance at DDW: 63.5% disease clearance in LUCENT-3 OLE
Key Questions
What four-year data was presented for Omvoh at DDW?
Omvoh showed 63.5% disease clearance in ulcerative colitis after four years in LUCENT-3 OLE. First for an IL-23p19 inhibitor.
What does Omvoh's data mean for Eli Lilly's immunology pipeline?
It demonstrates long-term durability amid GLP-1 dominance. Bolsters diversification and sales ramp potential.
How was the LUCENT-3 OLE study structured for Omvoh?
63.5% of patients achieving clearance at one year sustained it at four years. Presented at DDW for UC treatment.
Omvoh shows 63.5% four-year UC disease clearance in LUCENT-3 OLE, first for IL-23p19 inhibitor, presented at DDW. Bolsters LLY immunology pipeline durability amid GLP-1 dominance. Signals diversification and sales ramp potential.
Sources (2)
Updated May 6, 2026